Research And Views Archives | Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Archives... Don't Miss Anything, Ever!

Here you will find all the research and views that we post on Equitymaster. Use the tools to customize the results to suit your preference!

















Authors
 

Dabur: Sluggish topline, improved OPM

Oct 30, 2002

Dabur India, the ayurvedic products major, has reported a marginal 2% topline growth during the September quarter 2002. The company had reported a 7% topline growth during the June quarter. Cost efficiencies led to a 160 basis point expansion in operating margins, thus helping the company report nearly 24% growth in 2QFY03 net profit.

Dabur: Encouraging numbers…

Jul 31, 2002

Dabur India, the ayurvedic products major, has reported an encouraging 7% topline growth in June quarter. It ability to control costs led to a 100 basis point expansion in operating margins, thus helping the company report an over 30% growth in 1QFY03.

Dabur: In a trough

Jun 12, 2002

Slowdown and competition seems to have finally caught with Dabur Limited, India's largest ayurvedic FMCG company. In 4QFY02, the company actually reported an 8% decline in topline (the first negative in last few years). Its net profit saw a 67% decline during the said quarter.

Dabur: The pressure continues

Feb 5, 2002

Dabur India Limited, the ayurvedic products major, reported a marginal 1% increase in topline and a mere 2% growth in net profits during the December quarter of FY02.

Dabur: Sluggish numbers

Nov 28, 2001

Dabur India declared its first half FY02 results yesterday. The company reported a small 3% growth in turnover and a 13% growth in bottomline during this period. Comparing 2QFY02 with the corresponding quarter last year, Dabur managed a 5% growth in turnover and a 10% growth in net profits.

Dabur: Topline concerns

Jul 26, 2001

Dabur India has posted a 23% growth in 1QFY02 net profit to Rs 88 m. This growth in bottomline has come despite a negligible topline growth. Reduction of interest cost by 8% and an 11% jump in other income contributed to the company's bottomline growth.

Dabur 3QFY01 net jumps 42%

Jan 30, 2001

Dabur India, the ayurvedic products giant has declared a 42% jump in its 3QFY01 bottomline. This surge was on the back of a 10% jump in its topline during the period.

Dabur: In the reckoning

Aug 31, 2000

Dabur India, the 115 year old FMCG ‘ayurvedic’ company operates in the niche natural/ayurvedic products segment with a product folio of over 500 products. But despite its range, investors have been wary of investing in this company simply because of its unrelated diversifications and a family run business.

Dabur and Zandu: Distant cousins

May 19, 2000

To a layman Dabur and Zandu are companies operating in the niche ayurveda segment. At first glance these companies seem alike because of their 'ayurvedic' image. But probe a little further and you find two very different entities.

Disappointing results from Zandu

Feb 2, 2000

Zandu's turnover has declined 16.6% while the net profits have declined by 21%. The company has been sucessful in mainting its operating margins.

Dabur in talks for Zandu for possible merger

Dec 24, 1999

A possible merger between the two ‘Chyavanprash’ giants Dabur and Zandu is brewing. Dabur has reportedly offered the Zandu management a price of Rs. 6800-7000 per share. Both the management’s have however denied the talks.

Zandu posts 26% decline in net

Oct 27, 1999

Zandu Pharmaceuticals has posted a 26% decline in net during the quarter ended 30th September 1999. The company has been adversely affected by the sharp jump in interest and depreciation expenditure.


Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

MARKET STATS